Multiple sclerosis and neuromyelitis optica spectrum disorders in Argentina: comparing baseline data from the Argentinean MS Registry (RelevarEM)

Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: Data from a nationwide registry in Argentina

“…In this study based on data from the RelevarEM registry, 10 , 11 , 14 we evaluated 262 attacks and 270 therapeutic interventions in 131 NMOSD and MOG-AD patients followed and treated in Argentina. Neurologists registering patients in RelevarEM, were from every part of the country, ensuring a representative national sample of patients.…”

“…Of note, 37.5% of attacks analyzed in the NMOSD group were AQP4-ab-negative patients, which is a higher proportion of seronegative patients than in most NMOSD studies, but it is in line with previous studies from LATAM. 11 , 47 Seronegative patients are often a heterogeneous group of patients that could impact on the results. Although MOG-ab status in AQP4-ab-negative patients was published recently (performed in 53.7% [36/67] of seronegative NMOSD cohort) for this registry, 10 it is worth mentioning that we do not know how many seronegative patients were tested for MOG-ab in this sample.…”

“…Although there are no NMOSD and MOG-AD prevalence data in Argentina, epidemiologic information about MS/NMOSD ratio (21:1) and percentage of MOG-AD in AQP4-ab-negative NMOSD patients (27%) were recently published. 10 , 11 …”

“…[8][9][10] Although there are no NMOSD and MOG-AD prevalence data in Argentina, epidemiologic information about MS/NMOSD ratio (21:1) and percentage of MOG-AD in AQP4-ab-negative NMOSD patients (27%) were recently published. 10,11 Consensus recommendations on therapeutic strategies to treat NMOSD and MOG-AD have been recently published for the Latin America (LATAM) region. In the case of treatment of NMOSD attacks 2 : high-dose IV methylprednisolone (IVMP), therapeutic plasma exchange (PLEX) and/ or intravenous immunoglobulins (IVIgG), were all reported, although with little evidence for the last of these.…”

New epidemiological data of multiple sclerosis, the impact of psychopathological symptoms on the health-related quality of life of multiple sclerosis patients

“…We found the distribution of different the disease courses in our cohort to be 2.86% CIS, 7.14% PPMS, 24.29% SPMS, 65.71% RRMS while employing the novel phenotype-based classification [7] most of the cohort could be classified into RR/CIS phenotype (68.57%, 288 patients), progressive disease type was seen in 132 patients (31.43%). The distribution of the classical disease courses fell in line with recent data based on large registries from both low and high prevalence countries across Europe [82][83][84][85][86][87][88][89][90]. However, except for the Argentinian cohort, none of these studies have used the most recent McDonald criteria, furthermore not one of these studies have evaluated their population according to the novel phenotypic classification or have given data about the disease activity of their patients, they only supply information about the prevalence of MS and the distribution of the classical disease courses.…”